James Ziegler
Equibles does not estimate personal net worth.
Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IOVA alertsAbout James Ziegler
The proxy statement of Geron Corp reports total compensation of $2,392,709 for James Ziegler in fiscal 2025, including a base salary of $470,028. Disclosed compensation is on record for 2 fiscal years. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Frederick Vogt (CEO and General Counsel), Corleen Roche (CFO) and 7 others.
Affiliation history
-
Iovance Biotherapeutics, Inc. (IOVA)
Source not stated
Current -
Geron Corp (GERN)
Source not stated
Start not stated–2024-09-09
Company network
Leadership on record at Iovance Biotherapeutics, Inc.
- Frederick G. Vogt, Ph.D. CEO
- Frederick Vogt CEO, General Counsel
- Corleen Roche CFO
- Jean-Marc Bellemin CFO
- Igor Bilinsky COO
- Igor Bilinsky, Ph.D. COO
- Matthew W. Rosinack Chief Accounting Officer
- Michael C. Swartzburg Chief Accounting Officer
- Athena Countouriotis Board Member
- Iain Dukes Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Geron Corp (GERN) | Former Executive Vice President, Chief Commercial Officer (as of September 9, 2024) | $470,028 | $2,392,709 |
| 2024 | Geron Corp (GERN) | Executive Vice President, Chief Commercial Officer (as of September 9, 2024) | $163,221 | $5,768,744 |
Recent activity
No call appearances or filed executive changes recorded yet.